Orexo AB

ORX

SE0000736415

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:54 2024-05-14 am EDT			5-day change	1st Jan Change
19.5 ^SEK	+2.63%		+1.56%	+26.13%

May. 08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
Apr. 17	Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	MT

Orexo AB Provides Earnings Guidance for the Fourth Quarter and Full Year of 2020

November 04, 2020 at 05:10 am EST

Orexo AB (publ) provided earnings guidance for the fourth quarter and full year of 2020. For the quarter, the company announced net sales are expected to improve compared to third quarter 2020. For the full year, the company announced that net sales for 2020 will decline compared to 2019.

Latest news about Orexo AB

Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024	May. 08
Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	Apr. 17	MT
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	Apr. 17	CI
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	Apr. 02	MT
Orexo AB Announces Board Resignations	Mar. 22	CI
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	Mar. 14	MT
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	Mar. 13	CI
Orexo Plans SEK500 Million New Social Bond Issuance, Tender Offer	Mar. 08	MT
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	Feb. 12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	Feb. 12	CI
Transcript : Orexo AB, 2023 Earnings Call, Feb 08, 2024	Feb. 08
Orexo AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
US FDA Approves New Drug Application for Orexo's Opioid Overdose Rescue Medication	Nov. 28	MT
Orexo AB Announces FDA Acceptance of New Drug Application Filing for OX124	Nov. 28	CI
Transcript : Orexo AB, Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Orexo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Orexo AB Announces Changes in the Board of Directors	23-10-27	CI
Orexo AB Announces Nomination Committee Appointments	23-10-26	CI
Orexo AB Announces Resignation of Robin Evers as A Board Member	23-10-26	CI
Orexo's Opioid Use Disorder Drug Study Shows Unexpectedly High Treatment Response Rates	23-10-11	MT
Orexo AB Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids	23-10-11	CI
Orexo AB Announces Henrik Kjær Hansen Will Resign from the Board of Directors	23-10-02	CI
Orexo Files New US Drug Application for Opioid Overdose Medication	23-09-18	MT
Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio	23-09-18	CI
Orexo Obtains First US Patent for Nasal Epinephrine Product	23-08-29	MT

Chart Orexo AB

Duration

Period

More charts

Company Profile

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Sector

Pharmaceuticals

Calendar

2024-07-17 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Orexo AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
OREXO AB	+26.13%	60.36M
MERCK KGAA	+9.85%	72.5B
KYOWA KIRIN CO. LTD.	+13.69%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+60.16%	5.01B
YUHAN CORPORATION	+1.60%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-19.20%	2.46B
INDIVIOR PLC	+18.65%	2.44B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.46%	2.26B

Specialty & Advanced Pharmaceuticals

Orexo AB

Equities

ORX

SE0000736415

Pharmaceuticals

Orexo AB Provides Earnings Guidance for the Fourth Quarter and Full Year of 2020

Latest news about Orexo AB

Chart Orexo AB

Company Profile

Income Statement Evolution

Ratings for Orexo AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals